Musculoskeletal Changes After Physiotherapeutic Intervention in Podiatric Subjects (BIONEDIAN)
Musculoskeletal Changes Induced by Physiotherapeutic Intervention, and Their Impact on the Induction of Diabetic Foot Syndrome and Psychosocial Status in Type 2 Diabetes Mellitus
The recurrence of diabetic foot ulcers (DFU) is a key problem in podiatric care. It is very often given by biomechanical abnormalities frequently present in those patients. The aim of our randomized controlled study is to find possible changes as of plantar pressures as of biomechanics of the ankle and small joints in patients with type 2 diabetes mellitus with different degrees of neuropathy. During this project, investigators will examine the possible impact of 12-week lasting intervention program on the distribution of plantar pressures, joint mobility and muscle strength of lower limbs. The incidence of ulcerations / reulcerations and changes of psychosocial characteristics will be evaluated during the study period.
Approximately 60 patients with Type 2 diabetes mellitus will be included into the study. These patients will be randomized into 3 study groups - patients with type 2 DM with mild form of peripheral sensory neuropathy (20 subjects), patient with severe peripheral neuropathy (20 subjects) and those with diabetic foot syndrome, without active lesion (20 subjects). All patients will undergo 12 week lasting active intervention program consisting of recommendations by a physiotherapist focusing on the improvement of physical fitness, muscle strength and foot joint improvement. Control group will be consisted of 20 patients with healed diabetic foot.
The outcomes of this project will try to objectively verify in the randomized controlled trial the impact of exercise on lower limb biomechanics, mobility, self-sufficiency, quality of life in patients with type 2 diabetes mellitus at risk or already developed diabetic foot syndrome.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Anticipato)
Fase
- Non applicabile
Contatti e Sedi
Contatto studio
- Nome: Eliška Vrátná, Mgr.
- Numero di telefono: +420774549214
- Email: vratnae@gmail.com
Backup dei contatti dello studio
- Nome: Vladimíra Fejfarová, MD, PhD
- Numero di telefono: +420603877381
- Email: vlfe@medicon.cz
Luoghi di studio
-
-
-
Prague, Cechia, 14200
- Reclutamento
- Institute for Clinical and Experimental Medicine
-
Contatto:
- Eliška Vrátná, Mgr.
- Numero di telefono: +420774549214
- Email: vratnae@gmail.com
-
Contatto:
- Vladimíra Fejfarová, MD, PhD
- Numero di telefono: +420603877381
- Email: vlfe@medicon.cz
-
Sub-investigatore:
- Jitka Hazdrová, MD
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Type 2 diabetes mellitus
- sensoric neuropathy (mild - based on VPV 15-30 V or EMG results, severe - based on VPT above 50 V or EMG results)
- diabetic foot with healed diabetic foot ulcers, inactive Charcot foot
Exclusion Criteria:
- impossibility to exercise
- amaurosis
- non-compliance
- critical limb ischemia
- active ulcer, surgical wound
- active Charcot foot
- active carcinoma
- recent stroke (last 8 weeks)
- recent myocardial infarction (last 8 weeks)
- recent PTA, PCI, bypass (last 8 weeks)
- myopathy
- rheumatoid arthritis
- cox-, gonartrosis of 3rd -4th grade.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Separare
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: DF patient active
Patients with Type 2 diabetes mellitus and diabetic foot, whose have healed diabetic foot ulcers
|
12 week lasting exercise intervention
|
|
Comparatore attivo: DF patient control
Patients with Type 2 diabetes mellitus and diabetic foot, whose have healed diabetic foot ulcers
|
12 week lasting exercise intervention
|
|
Sperimentale: Diabetic patient with mild neuropathy
Patients with Type 2 diabetes mellitus with mild form of peripheral sensory neuropathy
|
12 week lasting exercise intervention
|
|
Sperimentale: Diabetic patient with severe neuropathy
Patients with Type 2 diabetes mellitus with severe form of peripheral sensory neuropathy
|
12 week lasting exercise intervention
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Biomechanics- plantar pressures
Lasso di tempo: changes after 12 weeks, 24 weeks
|
plantar pressures will be evaluated by pedobarograph (in Newtons)
|
changes after 12 weeks, 24 weeks
|
|
Biomechanics- biomechanics of the ankle
Lasso di tempo: changes after 12 weeks, 24 weeks
|
biomechanics of the ankle will be assessed by goniometry in angles
|
changes after 12 weeks, 24 weeks
|
|
Biomechanics- changes of foot joint angles
Lasso di tempo: changes after 12 weeks, 24 weeks
|
changes of foot joint agles will be evaluated by measurement of X-Rays bones angles - calcaneal pitch, talar-1st metatarsal angle and lateral Talocalcaneal angle
|
changes after 12 weeks, 24 weeks
|
|
Fitness - physical activity
Lasso di tempo: changes after 12 weeks, 24 weeks
|
The amount of physical activity will be assessed by IPAQ questioners
|
changes after 12 weeks, 24 weeks
|
|
Fitness - muscle strength
Lasso di tempo: changes after 12 weeks, 24 weeks
|
Muscle strength will be measured by dynamometry in Newtons
|
changes after 12 weeks, 24 weeks
|
|
Fitness - senior fitness
Lasso di tempo: changes after 12 weeks, 24 weeks
|
fitness will be assessed by seniorfittest containing 2 minutes step test (steps/2 min) and test of sitting (sits/30 seconds)
|
changes after 12 weeks, 24 weeks
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
ulceration/reulceration
Lasso di tempo: changes after 12 weeks, 24 weeks
|
detection of the incidence of ulceration/reulceration
|
changes after 12 weeks, 24 weeks
|
|
Psychosocial changes - quality of life
Lasso di tempo: changes after 12 weeks, 24 weeks
|
Quality of life will be evaluated by WHO-QoL Bref test (4 domains - high values mean bettr findings
|
changes after 12 weeks, 24 weeks
|
|
Psychosocial changes - depression
Lasso di tempo: changes after 12 weeks, 24 weeks
|
Depression status will be asessed by Geriatric Depression Scale (GDS) scale - minimum 0, maximum 30 points (higher then 9 points- mild form of depression, higher then 20 - severe depression
|
changes after 12 weeks, 24 weeks
|
|
Psychosocial changes - stress readaptation
Lasso di tempo: changes after 12 weeks, 24 weeks
|
Adaptation to stress will be detected by Stress Readaption Scale (0-400 points) - points higher then 150 - higher risk of worse stress readaptation and therefore higher risk of somatisation
|
changes after 12 weeks, 24 weeks
|
|
Metabolism - glucose control
Lasso di tempo: changes after 12 weeks, 24 weeks
|
Investigators will be loked for metabolic changes in diabetes control (HbA1c in mmol/mol, glycemia in mmol/l)
|
changes after 12 weeks, 24 weeks
|
|
Metabolism - lipid profile
Lasso di tempo: changes after 12 weeks, 24 weeks
|
The authors will control lipid profiles (Total-, HDL-, LDL-cholesterol in umol/l)
|
changes after 12 weeks, 24 weeks
|
|
Metabolism - myokines
Lasso di tempo: changes after 12 weeks, 24 weeks
|
Patients will be checked for changes in selected cytokines nad myokines (IL-4,6,7,8,15 in pg/ml, myostatin in pg/ml, irisin in ng/ml, FGF-21 in pg/ml)
|
changes after 12 weeks, 24 weeks
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Anticipato)
Completamento dello studio (Anticipato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- 546417
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .